The overall objective of this project is to provide support for the performance of clinical studies of the Cancer and Leukemia Group B at the Lombard Comprehensive Cancer Center at Georgetown University Medical Center. The LCCC/GUMC is an NCI-designated Comprehensive Cancer Center. Richard Pestell, M.D. was appointed Director of the Cancer Center in 2002. LCCC/GUMC has been a CALGB main member institution since March 1997. LCCCC/GUMC participates in the entire range of multimodality clinical studies including therapeutic studies, correlative science studies, and companion studies of quality of life, survivorship, and cost effectiveness analyses. LCCC faculty have been active in all three areas of CALGB activities: accrual, scientific leadership, and administrative tasks. At the present time 74 CALGB protocols are active at GUMC/LCCC. During the period from 2002-April 30, 2005 281 patients have been entered onto CALGB or Intergroup trials. LCCCC/GUMC faculty are represented on 14 Committees or Working Groups. Two LCCCC/GUMC faculty members served as study chairs and two faculty members participated in CALGB audits. It is anticipated that LCCCC/GUMC investigators will continue their activities in the CALGB and new/young faculty members will become involved in the scientific endeavors of the group as they grow in their careers. A recent merger of Georgetown University Medical Center with the nonprofit Medstar Health Network has allowed the establishment of a Network-wide IRB. As a result of centralized clinical trials management and approval, CALGB accrual should continue to increase during the next funding period. Lastly, two MedStar hospitals have become CALGB affiliated institutions and are actively contributing to the overall accrual of the Lombardi/MedStar clinical trials network.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
Organized Research Units
United States
Zip Code
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Martin, P; Jung, S-H; Pitcher, B et al. (2017) A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 28:2806-2812
Smith, Sonali M; Pitcher, Brandelyn N; Jung, Sin-Ho et al. (2017) Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol 4:e176-e182
Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2017) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 161:363-373
Bluethmann, Shirley M; Alfano, Catherine M; Clapp, Jonathan D et al. (2017) Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Res Treat 165:677-686
Dickson, M A; Mahoney, M R; Tap, W D et al. (2016) Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol 27:1855-60

Showing the most recent 10 out of 83 publications